Regeneus (ASX:RGS), a clinical-stage regenerative medicine technology company, today announced that the Japanese Patent Office has issued a decision to grant a patent covering the use of cancer vaccine technology for the treatment of a range of cancers in humans and animals.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that topical use of Sygenus gel for 6 weeks in adults with acne was well tolerated and showed a significant effect on the appearance of acne lesions as early as 3 weeks.
Anatara Lifesciences (ASX:ANR) has achieved a significant milestone in the United States of America after receiving a "complete" letter from the US Food and Drug Administration for the Technical Section of its Human Food Safety submission. The HFS is a major component of a New Animal Drug Application which is currently underway and is necessary for enabling the marketing of Detach(R) in the US.
Queensland Bauxite Limited (ASX:QBL) provides the Company's Quarterly Activities Report.
Nanollose Limited (ASX:NC6) is pleased to provide its Appendix 4C Cashflow Statement for the quarter ended 31 December 2017, together with the following operational update.
Respiratory technology company Rhinomed Limited (ASX:RNO) (OTCMKTS:RHNMF) can report another strong quarter of growth. During the quarter the company shipped and invoiced $602k ($1.2m for the half year) worth of stock to retailers, consumers and distributors. This reflects the strength of the Company's growing global retail distribution base.
Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $1,230,329 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive scheme.
